Tirzepatide | Luxbae Peptide Therapy

Home › Peptides › Tirzepatide
Dual GIP / GLP-1 Receptor Agonist

Tirzepatide Dual GIP/GLP-1

A first-in-class dual GIP and GLP-1 receptor agonist with the largest documented weight loss in any approved pharmacotherapy.

Book Free ConsultationCall 310.299.4444

What Tirzepatide actually is

Tirzepatide is a synthetic 39-amino-acid peptide engineered as a single agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The SURMOUNT-1 trial demonstrated 22.5% mean body-weight reduction at 72 weeks on the 15mg weekly dose — the largest weight-loss effect of any FDA-approved drug.1

FDA-approved as Mounjaro for type 2 diabetes (2022) and Zepbound for chronic weight management (2023). Dual incretin agonism produces stronger weight loss than GLP-1 alone, likely because GIP activity adds an additional metabolic and adipose-tissue signaling layer.2

At Luxbae, Tirzepatide is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Dual incretin agonism

Single peptide activates both GLP-1 and GIP receptors; combined effect on insulin secretion, appetite, gastric emptying, and adipose signaling exceeds GLP-1 alone.2

What the research shows

22.5% weight loss. SURMOUNT-1 mean at 15mg dose, 72 weeks.1

Robust A1C. Up to 2.0+ percentage points A1C reduction in SURPASS trials.3

Cardiovascular signals. SURPASS-CVOT positive readout in 2024.4

Side effects: Nausea, vomiting (especially titration), constipation or diarrhea, fatigue. Generally improves with dose stability.

FDA note: FDA-approved as Mounjaro (T2D) and Zepbound (obesity). Compounded versions are available under shortage rules and prescribed under medical supervision.

Tirzepatide FAQ

How is this better than semaglutide?
Dual incretin (GIP + GLP-1) produces stronger weight loss than GLP-1 alone (22.5% vs ~15%).

Side effects worse?
Similar profile to semaglutide; titration phase is the rate-limiter.

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
  2. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP/GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
  3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in T2D (SURPASS-2). N Engl J Med. 2021;385(6):503-515.

Start your Tirzepatide protocol at Luxbae

Call 310.299.4444Book Online
Medical disclaimer: This is educational information, not medical advice. Tirzepatide is investigational and many uses are not FDA-approved; treatments at Luxbae are administered under medical supervision by Dr. Ernst von Schwarz. Individual results vary.
Scroll to Top